Boards @MIT @VoyagerTx @BloomScience Emm; former CEO InCarda; alum @MITChemE @Penn; #PuertoRican#BLM#LatinX🇵🇷🌈🌊 follow @gracecolon on 🦋; opinions my own
Honored to have been included in @NatureBiotech’s 30th anniversary issue in the Voices of Biotech Leaders feature, and especially humbled to be included such accomplished company. Thanks to the @NatureBiotech team for your continued leadership in this incredible field!
Voices of biotech leaders
Nature Biotechnology asks a selection of leaders from across biotech to look at the future of the sector and make some predictions for the coming years https://t.co/jp04YcgXCV
The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón. https://t.co/yFzfJQvr7y
@charlene_liao Yes! We are so lucky to live about a mile from Vasona - it's my usual running/walking/birdwatching spot whenever I'm in town! Would love to have you join me some time - bring binoculars - awesome birds, some rare!
@DisavowTrump20 Proud to be a Boricua (and yes, we ARE US citizens). Bad Bunny is an amazing artist, humanitarian, and has done more for Puerto Rico and Latino/a/x than almost anyone, ever. #BenitoBowl#BenitoAntonioMartínezOcasio
On today’s #BiotechHangout@ColonGraceE, @TimOpler, @soowannaway (Graig Suvannavejh), & @EricSchmidt151 will cover market sentiment: 2026 biopharma market outlook, a bull/bear debate on the sector, companies gearing up for IPOs – are we ready?, deals: $GSK’s $2.2B acquisition of $RAPT, $JANX / $BMY $850M deal, policy: US exits the WHO, latest biotech funding bill topics, FDA’s MRD-negative guidelines for myeloma, company news: $CRVS Ph1 atopic dermatitis data (stock jump & competitive landscape), plus @TimOpler’s women’s health report & much more: https://t.co/Y2EeV1qUIg
On today's #BiotechHangout, @ColonGraceE, @cngarabedian, @SamFazeli8, @MatteisPaul, @YaronWerber, and special guest @johnbstanford will cover policy: NDAA provisions & implications for biotech, industry trends & deals: big Monday w/ $1.85B in biotech financings – most in one day?, $XBI’s sustained momentum & positive signals, $LLY’s acquisitive strategy, plus Fosun+$PFE deal for oral GLP-1, conferences: #ASH2025 ($AZN, $LLY vs $ONC, $JNJ/$LEGN vs $GILD/ACLX, $GMAB, $TERN), #ESMOAsia25 ($BNTX, Zelgen, $GSK, & other ADCs), $CGON at #SUO25, plus other data: $DYN positive DMD data, obesity news ($GPCR, $WVE, Ascletis), Endpoints 100 takeaways & much more: https://t.co/ytCrTb7zCM
@shut_thefu_ This kind of mindset where "women tempt and then blackmail men" and "men can't help their instincts" is toxic for both sides and we need to crush it.
@shut_thefu_ Another key barrier for women reaching the highest levels. We are banding together as CEOs, firm partners, board members, etc. to combat these kinds of issues. If we can't interact professionally and personally with men there are missed opportunities to network and lead.
https://t.co/5dl3CnQbhB Junk science should never drive policy. See my interview about our biotech efforts to combat misinformation being used to drive critical health decisions. It's bad for science, patients, the industry, and national competitveness.
@FCIty24604@Noirchick1 Agree. I adore Jimmy Stewart (and Hitchcock movies) but his character in this one was dark, obsessive, manipulative, etc - thoroughly unlikable and hard to watch. It’s still has some great directing, cinematography, mood, setting, etc but Rear Window is waaaaay better.